Cormorant Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Cormorant Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.87M	Sell	350,000 -50,000	-13%	-$703K	0.24%	45
2025 Q4	$4.83M	Sell	400,000 -100,000	-20%	-$1.36M	0.22%	34
2025 Q3	$6.79M	Buy	+500,000	New	+$4.71M	0.47%	33
2023 Q1	–	Sell	-550,000	Closed	-$20.3M	–	76
2022 Q4	$20.3M	Sell	550,000 -60,000	-10%	-$2.13M	1.36%	26
2022 Q3	$17.2M	Buy	+610,000	New	+$15.2M	1.2%	29

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Cormorant Asset Management's AMLX Position: Q1 2026 in Review

Cormorant Asset Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 13% in Q1 2026, selling an estimated $703K and leaving 350,000 shares worth $4.87M. The position accounts for 0.24% of the portfolio, ranked #45.

Cormorant Asset Management first reported a position in AMLX in Q3 2022 and has held it in 5 quarters since. The position peaked at $20.3M in Q4 2022. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

Cormorant Asset Management held 350,000 shares of Amylyx Pharmaceuticals worth $4.87M as of Q1 2026.
Cormorant Asset Management sold 50,000 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $703K.
Amylyx Pharmaceuticals made up 0.24% of Cormorant Asset Management's portfolio in Q1 2026, its #45 holding.
Cormorant Asset Management first reported a position in Amylyx Pharmaceuticals in Q3 2022 and has held it in 5 quarters since.
Cormorant Asset Management's Amylyx Pharmaceuticals position peaked at $20.3M in Q4 2022.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Cormorant Asset Management's 13F filing for Q1 2026, filed 15 May 2026.